文献速递青光眼

Xen 45 凝胶支架植入治疗开角型青光眼患者的两年结局:来自 Fight Glaucoma Blindness 登记的真实世界数据

Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry.
PubMed 文献 · Br J Ophthalmol · 2024-11-22

基于 Fight Glaucoma Blindness 观察性登记的前瞻性收集数据回顾性分析,评估 Xen 45 凝胶支架植入 24 个月的有效性与安全性。646 眼(515 例患者)术前眼压 21.4±7.6 mmHg、使用 2.7±1.3 种降眼压药物,24 个月后眼压 16.8±7.3 mmHg(平均降低 21.7%)、使用 1.2±1.4 种药物,完全成功率和条件成功率分别为 26% 和 48%。作者认为该支架提供可接受的长期疗效,但再手术和针刺发生率较高,联合白内障手术时效果较差。

要点

  • 24 个月完全成功率 26%、条件成功率 48%。
  • Xen 单独组完全成功率 33%、条件成功率 52%,高于 Xen+白内障组的 16% 和 42%。
  • 28.4% 的病例行滤过泡针刺,18% 行二次手术。

核心结论

  • Xen 45 凝胶支架植入为开角型青光眼提供可接受的长期疗效,但再手术和针刺发生率较高,联合白内障手术时效果较差。

研究设计与样本

  • 对 Fight Glaucoma Blindness 观察性登记前瞻性收集数据进行回顾性分析,纳入 515 例患者的 646 眼。
  • 完全成功定义为术前眼压降低≥20% 且 2 年时眼压≤18 mmHg 且≥6 mmHg、未行二次手术且未使用降眼压药物;条件成功定义类似但允许使用降眼压药物。

主要发现

  • 术前眼压 21.4±7.6 mmHg,使用 2.7±1.3 种降眼压药物,平均偏差 -10.2±8.4 dB。
  • 24 个月随访后眼压 16.8±7.3 mmHg(平均降低 21.7%),使用 1.2±1.4 种降眼压药物。
  • 24 个月完全成功率和条件成功率分别为 26% 和 48%。
  • Xen 单独组完全成功率 33%、条件成功率 52%,Xen+白内障组分别为 16% 和 42%。
  • 28.4% 的病例行滤过泡针刺,18% 行二次手术。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate efficacy and safety outcomes of the Xen 45 gel stent implant over 24 months of follow-up. METHODS: A retrospective analysis of prospectively collected data from the Fight Glaucoma Blindness observational registry. Complete success (CS) was defined as intraocular pressure (IOP) reduction ≥20% from preoperative and an IOP ≤18 mm Hg and ≥6 mm Hg with no secondary procedure at 2 years and without IOP-lowering medications. Qualified success (QS) was defined similarly, allowing the use of IOP-lowering medications. RESULTS: The Xen 45 gel stent implant was implanted in 646 eyes of 515 patients. Preoperative IOP was 21.4±7.6 (mean±SD) mm Hg on 2.7±1.3 IOP-lowering medication and mean deviation was -10.2±8.4 dB. After 24-month follow-up, IOP was 16.8±7.3 mm Hg (mean reduction of 21.7%) on 1.2±1.4 IOP-lowering medications. CS and QS rates at 24 months were 26% and 48%, respectively. CS and QS were higher in the Xen stand-alone group (33% and 52%, respectively) than in the Xen+cataract group (16% and 42%, respectively). Bleb needling was performed in 28.4% of cases, and 18% underwent a secondary procedure. CONCLUSIONS: The Xen 45 gel stent implant offers acceptable long-term efficacy for the treatment of open-angle glaucoma. However, there is a significant rate of reoperation and needling, and outcomes are less effective if combined with cataract surgery.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Arnould L, Balsat E, Hashimoto Y, et al. Two-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry. Br J Ophthalmol. 2024. PMID: 38789132. doi:10.1136/bjo-2023-325077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。